These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 16328054

  • 1. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP.
    Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
    Mukhopadhyay NK, Weisberg E, Gilchrist D, Bueno R, Sugarbaker DJ, Jaklitsch MT.
    Ann Thorac Surg; 2006 Mar; 81(3):1034-42. PubMed ID: 16488717
    [Abstract] [Full Text] [Related]

  • 3. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP.
    Clin Cancer Res; 2007 Feb 01; 13(3):1045-52. PubMed ID: 17289901
    [Abstract] [Full Text] [Related]

  • 4. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
    Chien CW, Yao JH, Chang SY, Lee PC, Lee TC.
    Toxicol Appl Pharmacol; 2011 Nov 15; 257(1):59-66. PubMed ID: 21889949
    [Abstract] [Full Text] [Related]

  • 5. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T, Nagano Y, Kouketsu A, Matsuura A, Maruyama S, Kurotaki M, Nakagawa H, Miyata N.
    J Med Chem; 2005 Feb 24; 48(4):1019-32. PubMed ID: 15715470
    [Abstract] [Full Text] [Related]

  • 6. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
    Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN.
    J Cell Biochem; 2004 May 15; 92(2):223-37. PubMed ID: 15108350
    [Abstract] [Full Text] [Related]

  • 7. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
    Rundall BK, Denlinger CE, Jones DR.
    Surgery; 2004 Aug 15; 136(2):416-25. PubMed ID: 15300209
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM.
    Cancer Res; 2001 Dec 01; 61(23):8492-7. PubMed ID: 11731433
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP.
    Exp Hematol; 2005 Jan 01; 33(1):53-61. PubMed ID: 15661398
    [Abstract] [Full Text] [Related]

  • 12. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
    Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH, Choi J, Ro S, Hyun YL, Lee JS, Kim CS.
    Anticancer Drugs; 2009 Oct 01; 20(9):815-21. PubMed ID: 19644355
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
    Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S.
    Int J Oncol; 2007 May 01; 30(5):1181-8. PubMed ID: 17390020
    [Abstract] [Full Text] [Related]

  • 15. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.
    Eur J Haematol; 2006 Jan 01; 76(1):42-50. PubMed ID: 16343270
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF.
    BMC Cancer; 2006 Jul 11; 6():183. PubMed ID: 16834771
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
    Vinodhkumar R, Song YS, Devaki T.
    Biomed Pharmacother; 2008 Feb 11; 62(2):85-93. PubMed ID: 17644301
    [Abstract] [Full Text] [Related]

  • 20. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
    Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP.
    Clin Cancer Res; 2006 Sep 15; 12(18):5570-7. PubMed ID: 17000694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.